Terry Milam, MD
Urology · Vancouver, WANPI 1700987963
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $187 of the $219 with a category attached, or 85.6%. 5 manufacturers reported payments, led by Neotract Inc. at 46.5% of the total. That places this record below the midpoint for urology clinicians in WA, where the typical reported total is $1,712.
Across 8 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$102
- Boston Scientific$59
- Olympus America Inc.$26
- Myovant Sciences Inc.$24
- Travere Therapeutics, Inc.$8
Across 5 payments — averaging $2059.93 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$10K
What the payments were for
- Food & beverage$18786%
- Education$3214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 2 | $102 |
| Boston Scientific | 2 | $59 |
| Olympus America Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 2 | $8 |
How this compares
$219 in reported general payments places this provider in the 20th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 104 | $84,826 |
| Tamsulosin Hcl | 392 | $7,439 |
| Finasteride | 258 | $3,878 |
| Potassium Citrate ErPotassium Citrate | 20 | $3,211 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 16 | $2,940 |
| Estradiol | 13 | $1,694 |
| Silodosin | 15 | $1,641 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $1,564 |
| Methenamine Hippurate | 32 | $1,437 |
| Trospium Chloride | 25 | $851 |
| Oxybutynin Chloride ErOxybutynin Chloride | 66 | $740 |
| Testosterone Cypionate | 23 | $599 |
| Oxybutynin Chloride | 19 | $437 |
| Dutasteride | 15 | $435 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $340 |
Paid to pharmacies, not to this prescriber.
Other urology in Vancouver
- Anthony BuiVancouver$55K
- Alan BickelVancouver$18K
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.